|
1）Claus R, Lübbert M. Epigenetic targets in hematopoietic malignancies. Oncogene. 2003; 22: 6489-96
|
|
|
|
2）Boultwood J, Wainscoat JS. Gene silencing by DNA methylation in haematological malignancies. Br J Haematol. 2007; 138: 3-11
|
|
|
|
|
|
3）Mistry AR, Pedersen EW, Solomon E, et al. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev. 2003; 17: 71-97
|
|
|
|
|
|
4）Shih AH, Abdel-Wahab O, Patel JP, et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012; 12: 599-612
|
|
|
|
|
|
5）Thol F, Damm F, Lüdeking A, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 2011; 29: 2889-96
|
|
|
|
|
|
6）Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; 363: 2424-33
|
|
|
|
|
|
7）Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011; 43: 309-15
|
|
|
|
|
|
8）Challen GA, Sun D, Jeong M, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2011; 44: 23-31
|
|
|
|
|
|
9）Gaidzik VI, Paschka P, Späth D, et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol. 2012; 30: 1350-7
|
|
|
|
|
|
10）Li Z, Cai X, Cai CL, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood. 2011; 118: 4509-18
|
|
|
|
|
|
11）Jan M, Snyder TM, Corces-Zimmerman MR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med. 2012; 4: 149ra118
|
|
|
|
|
|
12）Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012; 44: 1179-81
|
|
|
|
|
|
13）Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med. 2010; 362: 369-70
|
|
|
|
|
|
14）Chung YR, Schatoff E, Abdel-Wahab O. Epigenetic alterations in hematopoietic malignancies. Int J Hematol. 2012; 96: 413-27
|
|
|
|
|
15）Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010; 42: 181-5
|
|
|
|
|
|
16）Abdel-Wahab O, Adli M, LaFave LM, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell. 2012; 22: 180-93
|
|
|
|
|
|
17）Abdel-Wahab O, Jie G, Mazhar A, et al. Conditional deletion of Asxl1 results in myelodysplasia [abstract]. Blood (ASH Annual Meeting Abstracts) 2012; 120: 308
|
|
|
|
|
|
18）Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell. 2008; 14: 36-46
|
|
|
|
|
|
19）Dawson MA, Prinjha RK, Dittmann A, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011; 478: 529-33
|
|
|
|
|
|
20）Okada Y, Feng Q, Lin Y, et al. hDOT1L links histone methylation to leukemogenesis. Cell. 2005; 121: 167-78
|
|
|
|
|
|
21）Basecke J, Whelan JT, Griesinger F, et al. The MLL partial tandem duplication in acute myeloid leukaemia. Br J Haematol. 2006; 135: 438-49
|
|
|
|
|
|
22）Momparler RL, Momparler LF, Samson J. Comparison of the antileukemic activity of 5-AZA-2ʼ-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leuk Res. 1984; 8: 1043-9
|
|
|
|
|
|
23）Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10: 223-32
|
|
|
|
|
|
24）Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007; 109: 52-7
|
|
|
|
|
|
25）Maurillo L, Venditti A, Spagnoli A, et al. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. Cancer. 2012; 118: 1014-22
|
|
|
|
|
|
26）URL: http//www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommitte/UCM290509.pdf
|
|
|
|
|
|
27）Kantarjian HM, Jabbour E, Yee K, et al. First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML) [abstract]. Blood (ASH Annual Meeting Abstracts) 2013; 122: 497
|
|
|
|
|
|
28）Kuendgen A, Schmid M, Schlenk R, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer. 2006; 106: 112-9
|
|
|
|
|
|
29）Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008; 111: 1060-6
|
|
|
|
|
|
30）Garcia-Manero G, Assouline S, Cortes J, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 2008; 112: 981-9
|
|
|
|
|
|
31）Yen K, Lemieux R, Popovici-Muller J, et al. IHD1 mutant inhibitor induces cellular differentiation and offers a combination benefit with ara-C in a primary human Idh1 mutant AML xenograft model. Blood [abstract]. Blood (ASH Annual Meeting Abstracts) 2013; 122: 3946
|
|
|
|
|
|
32）Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013; 340: 622-6
|
|
|
|
|
|
33）Yen K, Wang F, Travins J, et al. AGI-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model. Blood [abstract]. Blood (ASH Annual Meeting Abstracts) 2013; 122: 240
|
|
|
|
|
|
34）Daigle SR, Olhava EJ, Therkelsen CA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013; 122: 1017-25
|
|
|
|
|
|
35）Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011; 20: 53-65
|
|
|
|
|
|
36）Grembecka J, He S, Shi A, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol. 2012; 8: 277-84
|
|
|
|
|